Cellnovo Targets 2018 Launch Of Insulin Micropump With Artificial Pancreas Tech
Executive Summary
Cellnovo has signed a commercial license agreement with digital health firm TypeZero to integrate its artificial pancreas software technology into Cellnovo’s digitally connected insulin patch pump. The integrated product is expected to launch in 2018.
You may also be interested in...
Senseonics, TypeZero Join Forces On Artificial Pancreas
Diabetes companies Senseonics and TypeZero Technologies have signed a research and development licensing agreement to develop an artificial pancreas.
Cellnovo Chooses BGM’s ‘No. 1’ Over JNJ For Diabetes Management System
Cellnovo is integrating Roche’s Accu-Chek blood glucose monitoring platform into the latest version of its mobile, all-in-one diabetes management system. The Swiss drug and diagnostics giant’s BGM technology will replace Johnson & Johnson’s LifeScan OneTouch Vita which Cellnovo has been using until now.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.